Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Summary

The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment

Timeline

Start

2020-12-21

Primary completion

2024-10-22

Completion

2024-10-22

Outcome

Met primary endpoint

registry analysis (other test); Secukinumab vs Ustekinumab; p = 0.002; Odds Ratio (OR) 3.647 (95% CI 1.601 to 8.311); Regression, Logistic NCT04632927 ↗

Drugs

Indications